<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03326830</url>
  </required_header>
  <id_info>
    <org_study_id>CHRO-2017-09</org_study_id>
    <secondary_id>2017-A01922-51</secondary_id>
    <secondary_id>CHRO-2017-09</secondary_id>
    <nct_id>NCT03326830</nct_id>
  </id_info>
  <brief_title>Prehospital High-Flow Nasal Oxygen Therapy</brief_title>
  <acronym>PRHOXY-1</acronym>
  <official_title>Prehospital High-Flow Nasal Oxygen Therapy in Patients With Acute Hypoxemic Respiratory Failure: A Randomized, Open-label, Bi-center, Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional d'Orléans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Régional d'Orléans</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present project is to compare High-Flow Nasal Oxygen therapy with Standard&#xD;
      Oxygen therapy, initiated in the prehospital setting in patients with acute hypoxemia&#xD;
      respiratory failure, in terms of oxygenation at arrival to the hospital and need of&#xD;
      mechanical ventilation during the subsequent 28 days&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with respiratory distress and an SpO2 below 90% in the prehospital setting will be&#xD;
      randomized to receive either high-flow nasal oxygen therapy through a dedicated device or&#xD;
      standard oxygen therapy through standard devices such as nasal cannula or face mask. Need of&#xD;
      mechanical ventilation either invasive or noninvasive from enrollment to day 28 and time&#xD;
      course of oxygenation between first SpO2 measured on scene and arrival to the hospital will&#xD;
      be the main outcome measures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2017</start_date>
  <completion_date type="Anticipated">January 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 21, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Bi-center, open-label, parallel, randomized trial with 1:2 allocation ratio (2 patients assigned to standard oxygen therapy for 1 patient assigned to High Flow Nasal Oxygen therapy)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>need of mechanical ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>cumulative incidence of the use of tracheal intubation or noninvasive ventilation (whichever comes first) from enrolment to day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoxemia</measure>
    <time_frame>1 hour</time_frame>
    <description>Frequency of hypoxemia, defined as sustained (at least 5 min) SpO2 below 90% (SpO2 will be continuously recorded throughout the prehospital medical care period) from the beginning of the intervention period until arrival at Emergency Department or other hospital ward.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe hypoxemia</measure>
    <time_frame>1 hour</time_frame>
    <description>Frequency of severe hypoxemia, defined as sustained (at least 5 min) SpO2 below 85% from the beginning of the intervention period until arrival at Emergency Department or other hospital ward.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>28 days</time_frame>
    <description>Probability of survival from inclusion to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2</measure>
    <time_frame>1 hour</time_frame>
    <description>Time course of SpO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>1 hour</time_frame>
    <description>Time course of respiratory rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>1 hour</time_frame>
    <description>Time course of heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tracheal intubation</measure>
    <time_frame>28 days</time_frame>
    <description>Cumulative incidence of tracheal intubation from inclusion to day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Noninvasive ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>Cumulative incidence of noninvasive ventilation use for acute respiratory failure from inclusion to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial pH</measure>
    <time_frame>1 hour</time_frame>
    <description>arterial pH (units) measured at hospital arrival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial PaCO2</measure>
    <time_frame>1 hour</time_frame>
    <description>arterial PaCO2 (mmHg) measured at hospital arrival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial PaO2</measure>
    <time_frame>1 hour</time_frame>
    <description>arterial PaO2 (mmHg) measured at hospital arrival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>1 hour</time_frame>
    <description>Dyspnea intensity as assessed by the patient him/herself at hospital arrival using the following dyspnea score: frank improvement: +2; mild improvement: +1; No change: 0; slight worsening: -1; frank worsening:-2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>Day 28</time_frame>
    <description>The number of serious adverse events during the intervention phase of the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Acute Respiratory Failure With Hypoxia</condition>
  <condition>Oxygen Inhalation Therapy</condition>
  <condition>Prehospital Setting</condition>
  <arm_group>
    <arm_group_label>Standard oxygen therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard oxygen therapy will be delivered using any device or combination of devices that are part of usual care: nasal oxygen, and mask with or without a reservoir bag and with or without the Venturi system. The flow will be tapered to target an SpO2 ≥ 95%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-flow nasal oxygen (HFNO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: High-flow nasal oxygen (HFNO) group Device that delivers humidified and warmed high-flow oxygen at flows between 30-60L/min HFNO will be initiated at a flow rate between 30-60 L/min and FiO2 titrated for a target of SpO2 ≥ 95%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High-flow nasal oxygen</intervention_name>
    <description>oxygen therapy will be delivered through a dedicated system, the Airvo2™ (Fisher&amp;Paykel, New-Zealand).</description>
    <arm_group_label>High-flow nasal oxygen (HFNO)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard oxygen therapy</intervention_name>
    <description>Oxygen therapy will be delivered using standard devices such as nasal canula or face mask with or without rebreathing bag</description>
    <arm_group_label>Standard oxygen therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  First SpO2 on scene &lt;90%&#xD;
&#xD;
          -  At least one other sign of respiratory distress defined by (a) respiratory distress&#xD;
             with a respiratory rate ≥ 25/min; (b) laboured breathing&#xD;
&#xD;
          -  No advance directives or known decisions of Do Not intubate or Do Not Ventilate order.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known COPD or other hypercapnic chronic respiratory failure&#xD;
&#xD;
          -  age &lt;18 years&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Anatomical factors precluding the use of a nasal cannula&#xD;
&#xD;
          -  Emergency intubation required&#xD;
&#xD;
          -  Patients with tracheostomy&#xD;
&#xD;
          -  Patient transported to a hospital not involved in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mai-Anh Nay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Régional d'Orléans</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thierry Boulain, MD</last_name>
    <phone>33 2 38 22 95 57</phone>
    <email>thierry.boulain@chr-orleans.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aurélie Despujols</last_name>
    <email>aurelie.despujols@chr-orleans.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHR d'ORLEANS</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie DESPUJOLS</last_name>
    </contact>
    <investigator>
      <last_name>May Anh NAY, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigade des Sapeurs Pompiers de Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Romain KEDZIEREWICZ, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Romain KEDZIEREWICZ, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Prekker ME, Feemster LC, Hough CL, Carlbom D, Crothers K, Au DH, Rea TD, Seymour CW. The epidemiology and outcome of prehospital respiratory distress. Acad Emerg Med. 2014 May;21(5):543-50. doi: 10.1111/acem.12380.</citation>
    <PMID>24842506</PMID>
  </reference>
  <reference>
    <citation>Kelly AM, Holdgate A, Keijzers G, Klim S, Graham CA, Craig S, Kuan WS, Jones P, Lawoko C, Laribi S; AANZDEM study group. Epidemiology, prehospital care and outcomes of patients arriving by ambulance with dyspnoea: an observational study. Scand J Trauma Resusc Emerg Med. 2016 Sep 22;24(1):113.</citation>
    <PMID>27658711</PMID>
  </reference>
  <reference>
    <citation>Stiell IG, Spaite DW, Field B, Nesbitt LP, Munkley D, Maloney J, Dreyer J, Toohey LL, Campeau T, Dagnone E, Lyver M, Wells GA; OPALS Study Group. Advanced life support for out-of-hospital respiratory distress. N Engl J Med. 2007 May 24;356(21):2156-64.</citation>
    <PMID>17522399</PMID>
  </reference>
  <reference>
    <citation>Fontanari P, Burnet H, Zattara-Hartmann MC, Jammes Y. Changes in airway resistance induced by nasal inhalation of cold dry, dry, or moist air in normal individuals. J Appl Physiol (1985). 1996 Oct;81(4):1739-43.</citation>
    <PMID>8904594</PMID>
  </reference>
  <reference>
    <citation>Sim MA, Dean P, Kinsella J, Black R, Carter R, Hughes M. Performance of oxygen delivery devices when the breathing pattern of respiratory failure is simulated. Anaesthesia. 2008 Sep;63(9):938-40. doi: 10.1111/j.1365-2044.2008.05536.x. Epub 2008 Jun 6.</citation>
    <PMID>18540928</PMID>
  </reference>
  <reference>
    <citation>Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur Respir J. 2020 May 14;55(5). pii: 2000892. doi: 10.1183/13993003.00892-2020. Print 2020 May.</citation>
    <PMID>32299867</PMID>
  </reference>
  <reference>
    <citation>Leonard S, Strasser W, Whittle JS, Volakis LI, DeBellis RJ, Prichard R, Atwood CW Jr, Dungan GC 2nd. Reducing aerosol dispersion by High Flow Therapy in COVID-19: High Resolution Computational Fluid Dynamics Simulations of Particle Behavior during High Velocity Nasal Insufflation with a Simple Surgical Mask. J Am Coll Emerg Physicians Open. 2020 May 29. doi: 10.1002/emp2.12158. [Epub ahead of print]</citation>
    <PMID>32838373</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>October 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory Insufficiency</keyword>
  <keyword>Oxygen Inhalation Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

